Supplementary Table1. Clinical characteristics of migraine with aura (MA) patients included in the study.

Clinical characteristics / Stage 1 sample / Stage 2 sample / Combined sample
No. of subjects
Men/women, no.
Age, y
Mean age at onset, y
Mean duration of one attack, h
Mean number of attacks, mo
Pure MA attacks/MA+MO attacks, %
Visual aura symptoms, %
Sensory aura symptoms, %
Dysarthria/aphasia, %
Nausea, %
Vomiting, %
Photophobia, %
Phonophobia, %
Unilateral location, %
Pulsating pain, % / 270
77/193
48 ± 13.49
19.45 ± 11.1
44.9 ± 23.65
2.6 ± 1.41
40.2/59.8
96.6
40.38
32.83
87.4
66.03
91.6
88.93
84.56
80.84 / 380
74/306
46 ± 12.5
19.1 ± 10.43
52.27 ± 22.22
2.7 ± 1.31
28.9/71.1
94.1
39.68
31.64
92.92
68.58
91.8
91.53
85.16
83.84 / 650
151/499
47 ± 12.97
19.25 ± 10.71
49.20 ± 23.1
2.65 ± 1.35
33.5/66.5
95.1
39.97
32.13
90.62
67.52
91.72
90.45
84.91
82.59

Supplementary Table 2:

Gene / ID / Genotyping Method / Call rate
Cases (%) / Call rate
Controls (%)
DBH / rs1076153 / SNPstream® / 97.9 / 99.2
DBH / rs2797849 / SNPstream® / 99.5 / 98.4
DBH / rs3025388 / SNPstream® / 97.9 / 99.2
DBH / rs2007153 / SNPstream® / 98.9 / 99.2
DBH / rs1108581 / SNPstream® / 98.7 / 99.5
DBH / rs2873804 / SNPstream® / 96.8 / 96.3
DBH / rs1541332 / Pyrosequencing / 97.1 / 99.2
DBH / rs2797853 / SNPtream® / 94.2 / 96.6
DBH / rs2097629 / Pyrosequencing / 98.2 / 96.8
DBH / rs1611131 / Pyrosequencing / 98.4 / 97.1
DBH / rs129882 / SNPstream® / 97.4 / 98.7
DRD2 / rs6279 / Taqman® assay / 97.6 / 97.9
DRD2 / rs2587548 / Taqman® assay / 95.0 / 98.4
DRD2 / rs7125415 / Taqman® assay / 99.7 / 99.7
DRD2 / rs4581480 / Taqman® assay / 98.9 / 99.5
DRD2 / rs7131056 / SNPstream® / 98.9 / 99.5
SLC6A3 / rs40184 / Taqman® assay / 97.9 / 98.2
SLC6A3 / rs27048 / Taqman® assay / 98.2 / 96.9
SLC6A3 / rs37022 / Taqman® assay / 96.6 / 98.9
SLC6A3 / rs37020 / Taqman® assay / 91.3 / 96.6
SLC6A3 / rs463379 / Taqman® assay / 99.5 / 100.0
SLC6A3 / rs403636 / Taqman® assay / 97.4 / 98.9
SLC6A3 / rs3756450 / Taqman® assay / 99.7 / 99.7
SLC6A3 / rs2078247 / Taqman® assay / 98.4 / 99.5

Legend to Supplementary Table 2:Genotyping methods and call rates of the 24 SNPs analyzed in sample 2. The GenomeLab SNPstream® Genotyping platform is marketed by Beckman Coulter (Fullerton, California, USA). The Taqman® platform is a registered trademark of Applied Biosystems (Foster City, California, USA). Pyrosequencing was performed on a Biotage® platform (Uppsala, Sweden). Primers and set-up conditions used for SNPstream® and pyrosequencing assays are available upon request. Taqman® assays were performed according to the manufacturer´s instructions.